New Global Survey Points to Key Issues, Needs and Gaps in Fight to End Smoking
The Foundation for a Smoke-Free World released findings today from a global survey to better understand smokers, their experiences, and challenges they face when they try to quit smoking. The survey also highlights their awareness regarding the harm caused by smoking and how their perceptions of cigarettes, alternative products, and nicotine influence their motivation to move away from smoking. The data will shape the development of research to determine the best solutions to accelerate the end of smoking across diverse cultures and economic conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180319005647/en/
Figure 1: Which of the following situations, if any, apply to you? (% - Top Three Answers per Country) (Graphic: Business Wire)
The 2018 State of Smoking Survey included 17,421 current smokers, ex-smokers, and non-smokers from 13 countries: Brazil, France, Greece, India, Israel, Japan, Lebanon, Malawi, New Zealand, Russia, South Africa, United Kingdom, United States. In parallel, a series of qualitative focus groups were carried out in seven countries (France, Greece, India, New Zealand, South Africa, United Kingdom, United States) to give additional context to the quantitative results. The survey was conducted by Kantar Public, an integrated consulting and research agency, which was engaged by the Foundation.
The primary findings are:
1. Smoking isn’t an isolated habit. Smokers consider it deeply integrated with their basic pleasures of life, such as eating, drinking, and socializing. Currently implemented cessation methods fail to take these into account, resulting in continued smoking.
2. Smokers know that smoking is harmful to their health, and many consider themselves in poorer health than non-smokers, yet they do not actively engage with their healthcare providers or discuss effective cessation or reduced-harm solutions with them. The healthcare system needs to better engage with smokers, and medical providers need more effective tools to help smokers quit.
3. There is confusion among smokers about the relative harms of smoking and less harmful alternatives. While people “smoke for the nicotine, but die from the tar,” there is still considerable misperception about the risks of nicotine. This impacts their motivation to quit or try reduced risk alternative products.
“I hope this survey will jolt many of the world’s one billion smokers into action to stop smoking, spark a meaningful discussion on the deeply complex reasons so many people continue to smoke, and make clear the urgent need to develop more effective communications and interventions to help smokers quit or substantially reduce their risks,” said Dr. Derek Yach, President of the Foundation for a Smoke-Free World. “By better understanding key drivers behind why people start smoking, barriers to quitting, and motivations to stop, we can help reduce the negative health consequences for many who are trapped in the cycle of addiction to combustible tobacco products.”
Specific findings from the global survey include:
- Smoking is closely associated with daily rituals and routines like waking up, meal time, coffee/tea breaks, and socializing. In some countries (such as Brazil, Greece, and Lebanon), cigarettes are often smoked with coffee or tea, and in many others, cigarettes are commonly smoked after meals. (See figure 1)
- In most countries, there was a significant desire to quit smoking. (See figure 2)
- Most smokers polled recognize that smoking is harmful to their health and self-report as being less healthy than non-smokers, yet they visit their healthcare providers less frequently than non-smokers. (See figures 3 and 4)
- The main driver that motivates smokers to quit or consider quitting is mainly their concern about their personal health. (See figure 5)
- Although a large majority of smokers surveyed tried quitting without assistance, those that sought assistance often switched to nicotine-replacement therapy and prescription medicines first. In some countries (i.e., France, Greece, Japan, Lebanon, New Zealand, Russia, UK, US), smokers reported using e-cigarettes and other nicotine replacement devices to cut down or quit smoking cigarettes. (See figure 6)
Further findings from this study are available at: https://www.smokefreeworld.org/sites/default/files/uploads/derek-yach-press-conference-presentation.pdf. High resolution images of the graphics are available at: https://www.dropbox.com/sh/0bw9ckaac0h7cu9/AAB1ihaAu9Ilr_aFdaxZq60ia?dl=0.
“The data demonstrates that by better understanding the unique experiences and struggles of the individual smoker, we can better support each individual’s quit journey,” said Dr. Yach. “In this age of personalized medicine, it is only logical that we should stop treating the world’s smokers as one homogeneous group and start developing and embracing a wide range of solutions that allow individual smokers to select the method that works best for his or her situation and, more importantly, reduce the harm, disease, and death that is caused by smoking.”
About the Foundation for a Smoke-Free World
The Foundation is an independent, private foundation formed and operated free from the control or influence of any third party. Philip Morris International, S.A. has provided the initial funding to the Foundation. The Foundation makes grants and supports medical, agricultural and scientific research to end smoking and its health effects, and to address the impact of reduced world-wide demand for tobacco.
Feinstein Kean Healthcare
Lynn Blenkhorn, 617-761-6766
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Cytox Expands Collaboration with AIBL to Identify Those Most at Risk to Rapidly Progress to Alzheimer’s24.9.2018 05:00 | Pressemelding
Cytox, a precision medicine company which today is commercializing polygenic risk scoring (PRS) approaches for assessing genetic risk for developing Alzheimer’s disease (AD) and other neurological diseases, has announced it has expanded its research collaboration with the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) to test new algorithms for identifying the pre-symptomatic and mild cognitively impaired people most at risk to progress to AD. Under the expanded agreement Cytox will assess genetic risk for accelerated development of AD using its current, commercially available, research use only approaches developed to run on the Thermo Fisher Scientific Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrument platform. AIBL will provide biobank samples together with associated longitudinal data from study research participants clinically diagnosed as cognitively normal, with mild cognitive impairment or with AD. Each subject has confirmed amyloid status
American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)21.9.2018 22:13 | Pressemelding
Glorious beaches by day and theme park fireworks by night just got more convenient for Philadelphia travelers. American Airlines announced today that it will begin nonstop flights to Orlando Melbourne International Airport (MLB) starting February 16, 2019. The Central Florida airport is conveniently located in the heart of the tourism region and is the closest airport to NASA rocket launches, Port Canaveral’s cruises and what critics call “some of the most beautiful beaches Florida has to offer.” The flights will depart Saturdays from Philadelphia at 8:05 a.m., arriving in Florida at 10:48 a.m. The Embraer 175 jet arrival time syncs perfectly with cruise ship noon early boarding. Melbourne Airport Express offers nonstop shuttle service to the port, and all major rental car companies are onsite. The return flight to PHL departs at 11:24 a.m. and arrives in PHL at 1:55 p.m., with enough time to connect to some of American’s largest international destinations, including recently announced
Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice21.9.2018 17:43 | Pressemelding
BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Amy Palladino has joined the agency as Executive Vice President, Managing Director in the agency’s U.S. Corporate Practice. Based in New York, Palladino will focus on senior client counsel and executive positioning for the agency’s largest corporate clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005507/en/ Amy Palladino Joins BCW (Burson Cohn & Wolfe) “Amy is a talented and highly experienced communications executive with a track record of solving clients’ complex challenges and building business through smart, integrated communications approaches,” said Chris Foster, President, North America, BCW. “Her creativity and judgement will be enormously valuable to our current and prospective clients.” Palladino has more than 20 years of experience advising global clients across numerous industries, including technology, healthcar
Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 16:41 | Pressemelding
Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo
Florian Winterstein Becomes New CEO of Jedox21.9.2018 15:46 | Pressemelding
The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 13:30 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+